147 results
Page 2 of 8
6-K
EX-99.1
edw 368zawob
26 Oct 23
Current report (foreign)
6:20am
6-K
EX-99.1
eomo61p9jwswku2odgb
18 Oct 23
Current report (foreign)
6:21am
6-K
EX-99.1
50wwsc7q
18 Oct 23
Current report (foreign)
6:20am
6-K
038xk9bpas h6
2 Oct 23
Current report (foreign)
6:17am
6-K
il8zuawj4 d2gruvndzx
28 Sep 23
Current report (foreign)
6:17am
6-K
rt1 qk77dqlr2fdi
11 Sep 23
Current report (foreign)
6:50am
6-K
EX-99.1
ehunx4aeim8lkpp
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
x53l0kbq2pn66 co
6 Jul 23
Current report (foreign)
6:18am
6-K
yrvgiw cqto7d2g
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
xk1o3 5q4ythxdd9
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
0neiucdlykd ac
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
4vq0 5u41ibrr9wz6b1e
30 May 23
Current report (foreign)
6:11am
6-K
o2ly0aux0g7
17 May 23
Current report (foreign)
6:02am
6-K
uuik lwkrqy8a9pd
11 May 23
Current report (foreign)
6:10am
6-K
9laav76gcu3seq
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
85luwosf
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
wtg337
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
jj86 49bj68mtt1rqws2
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
y7h1cc0g
8 Dec 22
Current report (foreign)
6:46am